Grant, Call number PAR-28-072
NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
National Eye Institute
- , Add deadline: choose a calendar
- United States
- Institution applies
- Ophthalmology, Pharmacology and
About
The National Eye Institute supports preclinical development of a treatment for visual disorders. Teams use a milestone-driven exploratory phase and can progress a single candidate toward regulatory submission and future clinical testing.
Topics
- NEI Translational Research Program, search World Wide
- R61/R33, search World Wide
- visual disorders, search World Wide
- preclinical development, search World Wide
- treatment, search World Wide
- milestone-driven, search World Wide
- exploratory phase, search World Wide
- regulatory submission, search World Wide
- clinical testing, search World Wide
Eligibility
Covers: Up to five years across both phases. R61 direct costs should rarely exceed USD 500,000 per year and R33 direct costs should not exceed USD 1 million per year.
The applicant must be a US institution.
Eligible US institutions include universities, research organizations, eligible businesses and other organizations named in the announcement. Foreign organizations and non-US components of US organizations cannot apply.
Source: simpler.grants.gov